Head-to-head Comparison of Quadruple Combination Therapy With Empagliflozin and Dapagliflozin in Patients With Poorly Controlled Type 2 Diabetes (T2D) Despite Three Existing Oral Antidiabetic Drugs (OAD)
Phase of Trial: Phase IV
Latest Information Update: 11 Jun 2019
Price : $35 *
At a glance
- Drugs Dapagliflozin (Primary) ; Empagliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 11 Jun 2019 Status changed from recruiting to completed, according to results presented at the 79th Annual Scientific Sessions of the American Diabetes Association.
- 11 Jun 2019 Results presented at the 79th Annual Scientific Sessions of the American Diabetes Association.
- 28 Nov 2018 New trial record